Patients without diabetes using GLP-1RAs are less likely to develop glaucoma compared with those who use other weight loss therapies.

The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 ...

MIT scientists have created a method to "paint" GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects ...

The incidence and risk for suicidality and self-harm were low for individuals given glucagon-like peptide-1 receptor agonists ...

1 Research Laboratory of Endocrinology ... Our review highlights that myokines such as brain-derived neurotrophic factor (BDNF), meteorin-like protein (Metrnl), secreted protein acidic and rich in ...

GLP-1 agonists, also known as incretin mimetics, are a class of medication that is primarily used to treat type 2 diabetes and, in some cases, obesity. "The glucagon-like peptide (GLP-1 ...

Glucagon-like peptide-1 (GLP-1) receptors, expressed in the central nervous system and peripheral tissues, have been found to affect gut motility. GLP-1 and its analog ROSE-010 have been shown to ...

It's called BRP (BRINP2-related peptide), and works by activating particular neurons in the brain in a similar way to GLP-1 (glucagon-like peptide-1 ... because the molecule activates different brain ...